PLx Pharma Inc. (PLXP)
PLx Pharma Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Sparta, NJ, US. The stock last traded at $0.09, up 0.00% on the session, giving a market capitalisation of $2.5M. On trailing twelve-month figures it carries a trailing P/E of -0.04, a net margin of -626.9%. Its beta of 3.92 implies it has historically moved more than the broad market.
PLx Pharma Inc. is a U.S.-based entity leveraging its innovative drug delivery platform technology, having successfully transitioned into the commercial stage. The company's primary offerings include Vazalore 325 mg, which is formulated for individuals facing vascular incidents like heart attacks and clot-induced strokes, as well as for the management of pain and inflammation. Additionally, they provide Vazalore 81 mg in the form of liquid-filled aspirin capsules. Looking ahead, their product development pipeline features PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, both of which are in Phase I clinical trials for addressing pain, inflammation, and fever. PLx Pharma makes its products available to consumers through a variety of retail avenues, including pharmacies, major retailers, supermarkets, and online sales channels. Founded in 2002, PLx Pharma Inc. is headquartered in Sparta, New Jersey.
PLx Pharma Inc. is most often compared with the following Healthcare names: